4D Molecular Therapeutics (FDMT) Revenue Growth (1y) (2021 - 2026)
4D Molecular Therapeutics (FDMT) Revenue Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 35.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 64.03% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - | 21,664.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21,664.29% |
| Dec 31, 2025 | 8,508,900.00% |
| Sep 30, 2025 | 2,900.00% |
| Jun 30, 2025 | 200.00% |
| Mar 31, 2025 | -50.00% |
| Dec 31, 2024 | 105.26% |
| Sep 30, 2024 | -99.99% |
| Jun 30, 2024 | -97.91% |
| Mar 31, 2024 | -90.60% |
| Dec 31, 2023 | -101.52% |
| Sep 30, 2023 | 3,940.80% |
| Jun 30, 2023 | 47.53% |
| Mar 31, 2023 | -75.55% |
| Dec 31, 2022 | 1,255.43% |
| Sep 30, 2022 | -63.40% |
| Jun 30, 2022 | -98.89% |
| Mar 31, 2022 | -39.05% |
| Dec 31, 2021 | -99.31% |
| Sep 30, 2021 | -81.59% |
| Jun 30, 2021 | 315.62% |